🩺What is Psoriasis?
The Dermatology Life Quality Index (DLQI) was developed by Finlay and Khan in 1994 at the University of Wales College of Medicine. It is a 10-item self-administered questionnaire covering 6 domains: symptoms and feelings (items 1-2), daily activities (items 3-4), leisure (items 5-6), work and school (item 7), personal relationships (items 8-9), and treatment (item 10). Each item is scored 0-3 (0=not at all, 1=a little, 2=a lot, 3=very much), with a maximum total score of 30. Higher scores indicate greater impairment of quality of life. The DLQI has excellent psychometric properties including test-retest reliability (r=0.99), internal consistency (Cronbach alpha 0.83-0.92), and construct validity demonstrated through correlations with disease severity measures and other quality of life instruments. The DLQI has been validated in over 55 languages and in more than 40 different skin diseases including psoriasis, atopic dermatitis, acne, vitiligo, hidradenitis suppurativa, rosacea, and skin cancer. The DLQI is recommended by the European Academy of Dermatology and Venereology (EADV), the International Psoriasis Council, and the Harmonising Outcome Measures for Eczema (HOME) initiative as the core outcome measure for quality of life in dermatology clinical trials.
📊Clinical Assessment & Risk Scoring
Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Psoriasis:
DLQI — Dermatology Life Quality Index
The Dermatology Life Quality Index (DLQI) is a 10-item, self-administered questionnaire designed to measure the impact of skin diseases on the quality of life of affected individuals. It is the most widely used dermatology-specific quality of life instrument worldwide.
🧬Diagnostic Logic & Scoring Breakdown
The DLQI total score is calculated by summing the responses to all 10 questions. Each question is scored 0 (not at all), 1 (a little), 2 (a lot), or 3 (very much). The minimum total score is 0 (no impairment of quality of life) and the maximum is 30 (extremely large impairment). If a question is left unanswered (not relevant), it is scored as 0. The DLQI can be analyzed as a total score or by domain: Symptoms and Feelings (items 1-2, max 6), Daily Activities (items 3-4, max 6), Leisure (items 5-6, max 6), Work/School (item 7, max 3), Personal Relationships (items 8-9, max 6), and Treatment (item 10, max 3). The DLQI is categorized into 5 bands: 0-1 no effect on quality of life, 2-5 small effect, 6-10 moderate effect, 11-20 very large effect, and 21-30 extremely large effect. The minimal clinically important difference (MCID) for DLQI varies by condition: psoriasis 3-5 points, atopic dermatitis 4-6 points, acne 3-5 points.
📢Clinical Significance & Implications
The Dermatology Life Quality Index (DLQI) is the most widely used dermatology-specific quality of life instrument in clinical practice and research worldwide. Its clinical significance is supported by over 25 years of validation across more than 40 skin diseases and 55 languages. The DLQI demonstrates excellent psychometric properties including test-retest reliability (r=0.99), internal consistency (Cronbach alpha 0.83-0.92), and construct validity with disease severity measures such as PASI for psoriasis (r=0.42-0.64), SCORAD for atopic dermatitis (r=0.52-0.65), and the acne-specific quality of life instruments. The DLQI is highly responsive to clinical change and is the most commonly used quality of life outcome measure in dermatology clinical trials. The DLQI has been adopted by major regulatory agencies including the FDA and EMA as a patient-reported outcome measure in dermatology drug development. The DLQI is the core outcome measure for quality of life in psoriasis (recommended by the International Psoriasis Council and GRAPPA), atopic dermatitis (recommended by the HOME initiative and EADV), acne, hidradenitis suppurativa, and vitiligo. The MCID for DLQI varies by condition: 3-5 points for psoriasis, 4-6 points for atopic dermatitis, and 3-5 points for acne. The DLQI has also been used to establish treatment response criteria: DLQI 0-1 is considered "treatment goal" for biologic therapy in psoriasis, and a reduction of >=5 points is considered a meaningful response in most conditions. Population norms are available from European general population studies with mean DLQI scores of 0.5-1.5 in healthy individuals.
💡 Clinical Assessment Scenario Example
A 32-year-old female with severe plaque psoriasis (PASI 18, BSA 25%) presents for quality of life assessment. Her DLQI responses: Q1 (itch/pain): 3 (very much), Q2 (embarrassed): 3 (very much), Q3 (shopping/home): 2 (a lot), Q4 (clothes): 3 (very much), Q5 (social/leisure): 2 (a lot), Q6 (sport): 1 (a little), Q7 (work/study): 2 (a lot), Q8 (partner/friends): 2 (a lot), Q9 (sexual): 1 (a little), Q10 (treatment): 2 (a lot). Total DLQI = 3+3+2+3+2+1+2+2+1+2 = 21. This falls in the extremely large effect range (21-30). Recommendation: Immediate referral to dermatology specialist. Given the severe disease and very large impact on quality of life, consider systemic therapy with biologic agents (TNF-alpha inhibitors, IL-17 inhibitors, or IL-23 inhibitors). Comprehensive psychosocial support and patient education. Assess for psoriatic arthritis. Schedule close follow-up for treatment response monitoring.
💊Common Medications & Interventions
The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Psoriasis:
⚠️Clinical Assessment Pitfalls
❌ Mistake: Scoring unanswered items as missing rather than 0
✅ Correction: According to DLQI scoring guidelines, items left unanswered (not relevant) should be scored as 0. The DLQI should only be considered invalid if more than 2 items are unanswered.
❌ Mistake: Using DLQI to compare across different skin diseases without adjustment
✅ Correction: DLQI scores can be compared across conditions, but the MCID differs by disease. Use disease-specific MCID values for interpreting change scores.
❌ Mistake: Not calculating domain scores in addition to total score
✅ Correction: The DLQI has 6 domain scores that provide clinically useful information about which aspects of quality of life are most affected. Always calculate and review domain scores.
🚑When to Seek Medical Attention
This reference supports clinical assessment of Psoriasis; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.
❓Frequently Asked Questions
Q: What is the minimal clinically important difference (MCID) for DLQI?
The MCID for DLQI varies by skin condition: psoriasis 3-5 points, atopic dermatitis 4-6 points, acne 3-5 points, and hidradenitis suppurativa 4-6 points. A reduction of >=4 points is generally considered a clinically meaningful improvement. A DLQI of 0-1 is considered a "treatment goal" for biologic therapy in psoriasis.
Q: Can DLQI be used for children?
Yes, the Children's DLQI (CDLQI) is available for children aged 4-16 years. It uses simpler language and includes a happy/sad face scale. The CDLQI has 10 items matching the adult DLQI and has been validated for pediatric dermatology.
Q: What is the recommended DLQI score for treatment goal in psoriasis?
A DLQI score of 0 or 1 ("no effect on quality of life") is widely accepted as the treatment goal for biologic therapy in psoriasis. This is known as the "DLQI 0/1 response" and is used as a treatment target in the European S3 Guidelines for psoriasis management.
Q: How long does it take to complete the DLQI?
The DLQI takes approximately 2-5 minutes to complete. It is one of the shortest and most efficient quality of life instruments in dermatology. The recall period is "the past week."
📚Evidence-Based References
Medically Reviewed By
Dr. Ahmed Abdelrahman
MD, MSc | Internal Medicine
Dr. Ahmed is a healthcare management consultant with over 15 years of experience in clinical practice and medical education.